Healthcare · Diagnostics Research · NASDAQ
| Market cap | $42.04B |
|---|---|
| Trailing P/E | — |
| Price / book | 22.4 |
| Price / sales | 14.4 |
| FCF yield | 0.2% |
| Dividend yield | — |
| Gross margin | 65.1% |
| Operating margin | -8.9% |
| Net margin | -5.7% |
| Revenue growth (YoY) | +35.9% |
| Revenue growth (3-yr annual) | +41.1% |
| EPS growth (YoY) | — |
| FCF/share growth (YoY) | +18.2% |
| Beta | 1.5 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics Research |
Next report: Feb 25, 2027 (Q4 2026, EPS estimate -$0.15). Beat the EPS estimate in 2 of 4 recent quarters.
| Quarter | Reported | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q3 2026 | Nov 5, 2026 | -$0.42 | -$0.28 | -50.0% | $793.98M |
| Q2 2026 | Aug 6, 2026 | -$0.47 | -$0.53 | +11.3% | $752.75M |
| Q1 2026 | May 7, 2026 | -$0.60 | -$0.55 | -9.1% | $696.64M |
| Q4 2025 | Feb 26, 2026 | $0.36 | -$0.53 | +167.9% | $665.50M |
Median target $407.50 from 22 analysts, ranging $280.00 – $500.00.
| Ticker | Company | Market cap | P/E |
|---|---|---|---|
| TMO | Thermo Fisher Scientific | $255.19B | 27.9 |
| DHR | Danaher | $160.10B | 27.3 |
| WAT | Waters | $89.71B | 31.7 |
| IDXX | IDEXX Laboratories | $54.33B | 46.5 |
| A | Agilent Technologies | $49.44B | 28.9 |
| IQV | IQVIA | $41.29B | 19.6 |
| MTD | Mettler-Toledo International | $33.93B | 36.8 |
| ILMN | Illumina | $30.34B | 38.2 |
Natera trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →
| Member | Chamber | Trade | Amount | Disclosed |
|---|---|---|---|---|
| Josh Gottheimer | House | Buy | $1,001 - $15,000 | Oct 15, 2025 |
| Josh Gottheimer | House | Buy | $1,001 - $15,000 | Sep 5, 2025 |
| Josh Gottheimer | House | Sell | $1,001 - $15,000 | Aug 11, 2025 |
| Josh Gottheimer | House | Buy | $1,001 - $15,000 | Dec 5, 2024 |